Logo

GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

Share this

GSK Collaborates with CEPI to Develop Vaccine Against Corona Virus

Shots:

  • GSK will utilize its adjuvant platform technology for developing a vaccine against the 2019-nCoV virus. The use of adjuvant technology lead to the production of more vaccine- thus increasing the availability to more people
  • GSK will engage with entities funded by the CEPI with the first of these agreements have been signed with Australia’s University of Queensland- which entered in an agreement with CEPI to develop a molecular clamp vaccine platform in Jan’2019
  • Both CEPI and GSK are committed to principles of equitable access and will work together to ensure that the principle governs the development- use- and access of 2019-nCoV vaccine developed via collaboration

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions